Northwest Biotherapeutics Inc. Announces Dedicated Leukapheresis Clinic

Northwest Biotherapeutics Inc. (OTCQB: NWBO) has announced the establishment of a dedicated leukapheresis clinic at The London Welbeck Hospital in London, United Kingdom. The announcement was made on April 21 2026 through a press release distributed by PRNewswire and reported by Finanznachrichten and Feedburner.

Strategic Rationale

The company, which develops DCVax® personalized immune therapies for solid tumor cancers, stated that the new clinic is intended to address potential constraints in leukapheresis capacity. By owning a dedicated facility, NWBO expects to:

  • Scale up its own programs that require the collection of patient immune cells for DCVax® and other T‑cell therapies.
  • Offer leukapheresis services to external parties when capacity allows.

The decision follows the company’s experience in its compassionate use program, where limited access to leukapheresis equipment was identified as a bottleneck.

Facility and Implementation Details

  • Location: The London Welbeck Hospital, a private medical facility on Harley Street with nearly 40 years of reputation.
  • Space: NWBO has secured dedicated clinical space within the hospital.
  • Build‑out: Initial equipment purchases were made in Q4 2025. Construction and outfitting are scheduled to be completed by June 2026.
  • Regulatory: The company is concurrently preparing regulatory license applications.
  • Equipment and Staff: A leukapheresis machine has already been delivered, and initial personnel have been selected.

Impact on Operations

The clinic is expected to enhance the company’s ability to collect patient immune cells efficiently. Each leukapheresis procedure takes approximately four hours, involving the filtration of blood to isolate white blood cells while returning red blood cells and plasma to the patient. By reducing dependence on external providers, NWBO aims to improve the reliability and speed of its immunotherapy development pipeline.

Company Profile

Northwest Biotherapeutics Inc. is a biotechnology firm listed on the OTC Bulletin Board. It specializes in discovering, developing, and commercializing immunotherapy products designed to stimulate immune responses against cancer. The company’s primary platform is DCVax®, a personalized immune therapy for solid tumors. As of April 21 2026, the company’s market capitalization was $315,120,000, with a closing share price of $0.19.

This article is based solely on the information provided in the supplied input.